ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

Madison Scientific, a Chicago-based startup developing a SmartShunt device, has raised $7 million in seed funding. The private medical device company said in a press release today that funding was ...

10 patients enrolled with 100% implantation success Adona's adjustable interatrial shunt is designed so it can be modified post-implantation to provide a more adaptive and personalized lifetime ...

PHOENIX -- The functional and quality-of-life benefits of creating a left-to-right shunt in the interatrial septum to offload failing hearts held up over the midterm in a series of small feasibility ...

BOSTON, MA—This week’s Technology and Heart Failure Therapeutics (THT) 2023 meeting featured more than a dozen talks on interatrial shunts to reduce left atrial pressures and volume overload in heart ...

Transcatheter implants designed to alleviate high left atrial (LA) pressures — which, as a possible way to treat heart failure (HF) once seemed like a long shot — are emerging as new stars of heart ...

ATLANTA, GA—The implantation of a Ventura (V-Wave) interatrial shunt failed to improve prognosis or reduce symptoms across a wide range of patients with heart failure (HF), results from a new ...

ATLANTA, GA (May 20, 2022) – Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented ...

For well-treated patients refractory to standard medications, the Ventura interatrial shunt was no better than sham in terms of primary effectiveness over nearly 2 years, defined by a hierarchical ...